Contact Us |







dayanews emp nodaya

 21 | April | 2016

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

Read more >

 13 | April | 2016

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents

Read more >

 16 | February | 2016

National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

Read more >

 10 | February | 2016

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

Read more >

 26 | January | 2016

Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016

Read more >

 12 | January | 2016

Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant

Read more >

Press Room3-29

Press Releases - | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |



Medical Key Opinion Leaders in Preeclampsia Join Pluristem’s Steering Committee

PLX-PAD cells offer promising potential treatment for preeclampsia; currently no treatment exists other than early delivery


HAIFA, ISRAEL, February 11, 2014 - Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, today announced it has formed a Preeclampsia Steering Committee to advance its PLacental eXpanded (PLX) cell therapies for the treatment of preeclampsia.


“Preeclampsia is an important indication for our PLX-PAD cells. Based on the dire need for a treatment and the potential of our cell therapy in this indication, we have made it a key priority to enter clinical trials for preeclampsia in the near future,” stated Pluristem Chairman and CEO Zami Aberman. “The caliber of medical and scientific thought leaders who have joined our Preeclampsia Steering Committee is a testament to the promise of our PLX cell therapy as a potential treatment for this disease.”   

Preeclampsia Steering Committee Member, Dr. Sibai, who was a moderator on the preeclampsia scientific forum, “Debate and Consensus: Preeclampsia Biomarkers in Clinical Practice, Are we ready?” at the Society for Maternal Fetal Medicine in New Orleans on Feb 5, 2014, commented, “For almost a thousand years, physicians have had no therapy to offer women with preeclampsia. A safe and effective therapy is needed to treat these women and prolong gestation. Pluristem’s PLX cells are a unique potential therapy because they originate from the placenta, which plays a key role in preeclampsia.”

Pluristems Preeclampsia Steering Committee:


Prof. James M. Roberts, M.D.

University of Pittsburgh

Professor, Department of Obstetrics, Gynecology and Reproductive Sciences

Professor of Epidemiology, Senior Scientist, Magee-Women’s Research Institute 


Prof. George R. Saade, M.D.

University of Texas Medical Branch

Professor, Division Chief Obstetrics & Gynecology


Prof. Baha M. Sibai, M.D.

University of Texas Medical School

Visiting Professor


Dr. David Williams, PhD FRCP

University College London

Honorary Senior Lecturer, Maternal & Fetal Medicine, Institute for Women's Health, Faculty of Population Health Sciences


Prof. Simcha Yagel, M.D.

Hadassah Medical Center, Israel

Head Division of Obstetrics and Gynecology at Hadassah Medical Center

Head of the Israeli Association of Placental Study 


The Preeclampsia Steering Committee will guide Pluristem’s preeclampsia program including advising on various stages of clinical trials, from the design of the study protocol through processing patient feedback up to the final study report. Committee members have vast knowledge of preeclampsia and a commitment to finding a treatment.  

In preclinical studies, PLX cells have been shown to be safe and an effective treatment for preeclampsia. In November 2013, Pluristem announced that PLX cells proved to be safe in an animal study assessing maternal and fetal toxicity. The Company announced in May 2013 that PLX cells improved several parameters of preeclampsia in animal models of the disease.


About Preeclampsia

Preeclampsia is one of the most common medical complications of pregnancy, and one of the leading known causes of premature births, stillbirths and early neonatal and maternal deaths. If left untreated it can progress to eclampsia, the life-threatening occurrence of seizures during pregnancy. The only known treatment for preeclampsia is abortion or delivery. The disease occurs after the 20th week of pregnancy, and is characterized by high blood pressure and significant amounts of protein in the urine or end-organ dysfunction. According to the World Health Organization, preeclampsia occurs in approximately 6–8% of pregnancies worldwide. It is estimated that preeclampsia costs the global health care system $3 billion annually.


About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information, the content of which is not part of this press release.


Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss the potential of our PLX-PAD cells to provide therapy for preeclampsia, conducting clinical trials in preeclampsia and the Preeclampsia Steering Committee meeting its expected goals. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.




Pluristem Therapeutics Inc.:

Karine Kleinhaus, MD, MPH

Director of Investor Relations


This email address is being protected from spambots. You need JavaScript enabled to view it.


Daya Lettvin
Investor & Media Relations Director

This email address is being protected from spambots. You need JavaScript enabled to view it.








catom 03

catom 01

This email address is being protected from spambots. You need JavaScript enabled to view it.

catom 13




The content, text, graphics, data, and services offered herein (the "Content") are provided solely to educate users of this web site on Pluristem and the goods and/or services it provides.  Nothing in the Content should be considered, or used as a substitute for, medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Reliance on the Content or any portion thereof, or other visitors to the web site, is solely at your own risk.